Gubra A/S (CO:GUBRA) — Market Cap & Net Worth
Market Cap & Net Worth: Gubra A/S (GUBRA)
Gubra A/S (CO:GUBRA) has a market capitalization of $927.11 Million (Dkr5.93 Billion) as of August 9, 2026. Listed on the CO stock exchange, this Denmark-based company holds position #9241 globally and #46 in its home market, demonstrating a -3.20% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Gubra A/S's stock price Dkr362.80 by its total outstanding shares 16333032 (16.33 Million). See Gubra A/S capital reinvestment ratio to understand how much of operating cash flow is reinvested back into capital assets.
Gubra A/S Market Cap History: 2023 to 2026
Gubra A/S's market capitalization history from 2023 to 2026. Data shows growth from $319.43 Million to $927.11 Million (42.87% CAGR).
Gubra A/S Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Gubra A/S's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.50x
Gubra A/S's market cap is 0.50 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.78x
Gubra A/S's market cap is 0.78 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $319.43 Million | $205.00 Million | -$44.52 Million | 1.56x | N/A |
| 2024 | $1.59 Billion | $265.74 Million | -$36.50 Million | 6.00x | N/A |
| 2025 | $1.32 Billion | $2.64 Billion | $1.69 Billion | 0.50x | 0.78x |
Competitor Companies of GUBRA by Market Capitalization
Companies near Gubra A/S in the global market cap rankings as of August 9, 2026.
Key companies related to Gubra A/S by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #428 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #547 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- Samsung Biologics Co Ltd (KO:207940): Ranked #555 globally with a market cap of $48.81 Billion USD ( ₩72.03 Trillion KRW).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $496.07 |
| #428 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $784.36 |
| #547 | Argen-X | BR:ARGX | $49.55 Billion | €763.20 |
| #555 | Samsung Biologics Co Ltd | KO:207940 | $48.81 Billion | ₩1556000.00 |
Gubra A/S Historical Marketcap From 2023 to 2026
Between 2023 and today, Gubra A/S's market cap moved from $319.43 Million to $ 927.11 Million, with a yearly change of 42.87%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Dkr927.11 Million | -29.89% |
| 2025 | Dkr1.32 Billion | -17.07% |
| 2024 | Dkr1.59 Billion | +399.20% |
| 2023 | Dkr319.43 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 9th, 2026 the market cap of Gubra A/S was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $927.11 Million USD |
| MoneyControl | $927.11 Million USD |
| MarketWatch | $927.11 Million USD |
| marketcap.company | $927.11 Million USD |
| Reuters | $927.11 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Gubra A/S
Gubra A/S, a disease-agnostic techbio company, focuses on the peptide-based drug discovery and preclinical contract research services in Europe, North America, and internationally. It operates through three segments: Preclinical Contract Research (CRO), Biotech, and Gubra Green. The company offers preclinical contract research and development services within metabolic and fibrotic diseases for th… Read more